It's time to warm up to hyperthermic intraperitoneal chemotherapy for patients with ovarian cancer (Q57212815)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30249527 AND SRC:MED&resulttype=core&format=json

24 April 2020

title

It's time to warm up to hyperthermic intraperitoneal chemotherapy for patients with ovarian cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30249527 AND SRC:MED&resulttype=core&format=json

24 April 2020

1 reference

1 reference

2

Dennis S Chi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30249527 AND SRC:MED&resulttype=core&format=json

24 April 2020

1

Oliver Zivanovic

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30249527 AND SRC:MED&resulttype=core&format=json

24 April 2020

3

Olga Filippova

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30249527 AND SRC:MED&resulttype=core&format=json

24 April 2020

Roisin E. O'Cearbhaill

series ordinal

6

object named as

Roisin E O'Cearbhaill

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30249527 AND SRC:MED&resulttype=core&format=json

24 April 2020

author name string

Leslie M Randall

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30249527 AND SRC:MED&resulttype=core&format=json

24 April 2020

Robert E Bristow

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30249527 AND SRC:MED&resulttype=core&format=json

24 April 2020

language of work or name

English

0 references

publication date

22 September 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30249527 AND SRC:MED&resulttype=core&format=json

24 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30249527 AND SRC:MED&resulttype=core&format=json

24 April 2020

volume

151

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30249527 AND SRC:MED&resulttype=core&format=json

24 April 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30249527 AND SRC:MED&resulttype=core&format=json

24 April 2020

page(s)

555-561

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30249527 AND SRC:MED&resulttype=core&format=json

The resurgence of platinum-based cancer chemotherapy

24 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Understanding cisplatin resistance using cellular models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Principles and practice of intraperitoneal chemotherapy for ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

7 January 2021

Peritonectomy procedures

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Are there intra-operative hemodynamic differences between the Coliseum and closed HIPEC techniques in the treatment of peritoneal metastasis? A retrospective cohort study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Reduction of cellular cisplatin resistance by hyperthermia—a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Effects of temperature on the interaction of cisplatin and carboplatin with cellular DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Chemotherapy delay after primary debulking surgery for ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

The cellular and molecular basis of hyperthermia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and -resistant tumour cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage IIIC/IV ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Peritonectomy procedures and HIPEC in the treatment of peritoneal carcinomatosis from ovarian cancer: Long-term outcomes and perspectives from a high-volume center

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case-control study on survival in patients with two year follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

The role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Primary peritoneal serous carcinoma treated by cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy. A multi-institutional study of 36 patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Hyperthermic intraperitoneal chemotherapy with cisplatin and paclitaxel in advanced ovarian cancer: a multicenter prospective observational study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Incidence and management of pancreatic leaks after splenectomy with distal pancreatectomy performed during primary cytoreductive surgery for advanced ovarian, peritoneal and fallopian tube cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC–IV epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Brief Report About the Role of Hyperthermic Intraperitoneal Chemotherapy in a Prospective Randomized Phase 3 Study in Recurrent Ovarian Cancer From Spiliotis et al.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria and AGO Switzerland Regarding the Use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

The Role of Heated Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: Hope or Hoax?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Intraperitoneal chemotherapy in ovarian cancer remains experimental

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Intraperitoneal chemotherapy in patients with advanced ovarian cancer: the con view

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Neoadjuvant chemotherapy in ovarian cancer revisited

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Activity of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with cisplatin and doxorubicin in women with recurrent, platinum-resistant ovarian cancer: preliminary clinical experience.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2018.09.007

Selective lethal effect of supranormal temperatures on human neoplastic cells.

7 January 2021

1 reference

12 December 2020

Intraperitoneal carboplatin: rationale and experience

1 reference

12 December 2020

Theoretical and experimental bases of intraperitoneal chemotherapy.

1 reference

12 December 2020

Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies

1 reference

12 December 2020

Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis

1 reference

12 December 2020

Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC)

1 reference

12 December 2020

HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian c

1 reference

12 December 2020

Low-dose pressurized intraperitoneal aerosol chemotherapy (PIPAC) as an alternative therapy for ovarian cancer in an octogenarian patient

1 reference

12 December 2020

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for First Relapse of Ovarian Cancer.

1 reference

12 December 2020

10.1016/J.YGYNO.2018.09.007

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30249527 AND SRC:MED&resulttype=core&format=json

24 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30249527 AND SRC:MED&resulttype=core&format=json

24 April 2020

PubMed publication ID

30249527

1 reference